mRNA Vaccines: Reasonable Concerns About the Consequences Using the Example of Covid-19 Vaccines

Kolevatykh M. A.
PhD (Engineering), Senior Researcher¹

1 - All-Russian Institute of Scientific and Technical Information of the Russian Academy of Sciences, Moscow, Russian Federation

Kolevatykh M. A.; e-mail: marinakolevatykh@mail.ru

None declared.

The study had no sponsorship.

The work is devoted to the analysis of scientific literature data on the consequences of vaccination with foreign mRNA vaccines against COVID-19. Evidence is presented for the presence of delayed, not immediately apparent clinically serious consequences. Particular attention is paid to the theory of «spikeopathy» – the pathogenetic effect of vaccines caused by the SARS-CoV-2 spike protein. Three potential pathogenetic mechanisms are considered that could explain the toxicity observed with the use of mRNA vaccines against COVID-19: 1) chemical toxicity of lipid nanoparticles, 2) direct toxicity of the spike protein, the expression of which is induced by vaccines, 3) destructive effects of the immune response to the protein spike. Evidence is provided of contamination of mRNA vaccines with plasmid DNA, which includes the promoters of the simian virus (SV40), associated with cancer in humans, and metal particles. It has been shown that booster doses of mRNA vaccines may worsen the immune system in immunocompromised individuals. It was noted that after the peaks of increased mortality in 2020 and 2021 due to COVID-19 disease in Russia, no further peaks of increased mortality were observed, while in Europe there was a high mortality rate in 2022 and 2023. The situation was assessed and a conclusion was made about the need for assessments of the possible consequences of vaccination, taking into account delayed consequences.

mRNA vaccines, recombinant vaccines, gene therapy, lipid nanoparticles, side effects

10.29234/2308-9113-2024-12-4-69-84

1. Anderson S. CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness. U.S. Food & Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee meeting. 2020. Available at:https://stacks.cdc.gov/view/cdc/97349

2. Barmada A., Klein, J., Ramaswamy, A., Brodsky N.N., Jaycox J.R., Sheikha H., Jones K.M., Habet V., Campbell M., Sumida T.S., et al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis. Sci. Immunol. 2023; 8(83): eadh3455, doi: 10.1126/sciimmunol.adh3455

3. Baumeier C., Aleshcheva G., Harms D., Gross U., Hamm C., Assmus B., Westenfeld R., Kelm M., Rammos S., Wenzel P., Münzel T., Elsässer A., Gailani M., Perings C., Bourakkadi A., Flesch M., Kempf T., Bauersachs J., Escher F., Schultheiss H.P. Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series. Int J Mol Sci. 2022; 23(13): 6940, doi: 10.3390/ijms23136940

4. Boretti A. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review. Clin Exp Med. 2024; 24(1): 23, doi: 10.1007/s10238-023-01264-1

5. Dopp K., Seneff S. COVID-19 and all-cause mortality data by age group reveals risk of COVID vaccine-induced fatality is equal to or greater than the risk of a COVID death for all age groups under 80 years old as of 6 February 2022. Vixra.org. 2022 [Электронный ресурс]. Режим доступа: https://vixra.org › pdf › 2202.0084v1.pdf

6. Ha J., Song M.C., Park S., Kang H., Kyung T., Kim N., Kim D.K., Bae K., Lee K.J., Lee E., Hwang B.S., Youn J., Seok J.M., Park K. Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study. Vaccine X. 2024; 16: 100446, doi: 10.1016/j.jvacx.2024.100446

7. Irrgang P., Gerling J., Kocher K., Lapuente D., Steininger P., Habenicht K., Wytopil M., Beileke S., Schäfer S., Zhong J., Ssebyatika G., Krey T., Falcone V., Schülein C., Peter A.S., Nganou-Makamdop K., Hengel H., Held J., Bogdan C., Überla K., Schober K., Winkler T.H., Tenbusch M. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2023; 8(79): eade2798, doi: 10.1126/sciimmunol.ade2798

8. Kuhbandner C., Reitzner M. Estimation of Excess Mortality in Germany During 2020-2022. Cureus 2023; 15(5): e39371, doi: 10.7759/cureus.39371

9. Kuhn C.C., Basnet N., Bodakuntla S., et al. Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein. Nat Commun 2023; 14(1): 620, doi: 10.1038/s41467-023-36279-5

10. Manno E.C., Amodio D., Cotugno N., et al. Higher Troponin Levels on Admission are associated With Persistent Cardiac Magnetic Resonance Lesions in Children Developing Myocarditis After mRNA-Based COVID-19 Vaccination. The Pediatric Infectious Disease Journal 2023; 42(2): 166-171, doi: 10.1097/inf.0000000000003762

11. McKernan K., Helbert Y., Kane L.T., McLaughlin S. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. 2023, doi: 10.31219/osf.io/b9t7m OSF Preprints. Available at: https://osf.io/preprints/osf/b9t7m

12. Mead M.N., Seneff S., Wolfinger R., Rose J., Denhaerynck K., Kirsch S., McCullough P.A. COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. Cureus 2024; 16(1): e52876, doi: 10.7759/cureus.52876

13. Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., Igyártó B.Z. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 2021; 24(12): 103479, doi: 10.1016/j.isci.2021.103479

14. Palmer M., et al. mRNA Vaccine Toxicity. 2023. Available at: https://archive.org/download/books-buecher-literature/mRNA­_vaccine­_toxicity-1­_0­%20%28Doctors­%20for­%20COVID­%20Ethics­%20-­%202023%29.pdf

15. Parry P.I., Lefringhausen A., Turni C., Neil C.J., Cosford R., Hudson N.J., Gillespie J. 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. Biomedicines 2023; 11(8): 2287, doi: 10.3390/biomedicines11082287

16. Rodríguez Y., Rojas M., Beltrán S., Polo F., Camacho-Domínguez L., Morales S.D., Gershwin M.E., Anaya J.M. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022; 132: 102898, doi: 10.1016/j.jaut.2022.102898

17. Trougakos I.P., Terpos E., Alexopoulos H., Politou M., Paraskevis D., Scorilas A., Kastritis E., Andreakos E., Dimopoulos M.A. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022; 28(7): 542-554, doi: 10.1016/j.molmed.2022.04.007

18. Uversky V.N., Redwan E.M., Makis W., Rubio-Casillas A. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel) 2023; 11(5): 991, doi: 10.3390/vaccines11050991

19. Yamamoto M., Kase M., Sano H., Kamijima, R., Sano S. Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion. J. Cutan. Immunol. Allergy 2022; (6): 18-23, doi: 10.1002/cia2.12278

20. Shimabukuro T. Update: v-safe after vaccination health checker. Advisory Committee on Immunization Practices (ACIP), April 19, 2023 Meeting. Available at: https://www.cdc.gov/acip/downloads/slides-2023-04-19/04-COVID-Shimabukuro-508.pdf

21. EuroMOMO. Excess mortality graphs. Available at: https://www.euromomo.eu/graphs-and-maps#excess-mortality

22. Global Vaccine Data Network. 99 million people included in largest global vaccine safety study. Available at: https://globalvaccinedatanetwork.org/node/981

23. Izbytochnaya smertnost' v Rossii. [Excess mortality in Russia.] Available at: https://gogov.ru/articles/natural-increase/excess-mortality (In Russ.)

24. React19. 3400+ COVID Vaccine Publications and Case Reports. 2022. Available at: https://react19.org/1250-covid-vaccine-reports